Need help finding what you are looking for?
Contact Us
PUBLISHER: Grand View Research | PRODUCT CODE: 1552861
PUBLISHER: Grand View Research | PRODUCT CODE: 1552861
Fabry Disease Treatment Market Size, Share & Trends Analysis Report By Solution, By Treatment (Enzyme Replacement Therapy), By Route of Administration, By Distribution Channel, By Region, And Segment Forecasts, 2024 - 2030
PUBLISHED:
PAGES: 100 Pages
DELIVERY TIME: 2-10 business days
SELECT AN OPTION
Fabry Disease Treatment Market Growth & Trends:
The global fabry disease treatment market size is estimated to reach a value of USD 4.93 billion by 2030, according to a new report by Grand View Research, Inc., exhibiting a CAGR of 9.9% from 2024 to 2030. Rising cohort of Fabry disease, increasing adoption of novel therapies such as chaperone treatment, and potential approval of pipeline drugs including substrate reduction therapies and enzyme replacement therapies are providing a fillip to the market.
Fabry disease is a rare inherited lysosomal storage disorder caused by genetic mutation that interferes with function of alpha galactosidase enzyme. Fabry disease generally has a late onset with mild symptoms, due to which several patients are often undiagnosed. Standard of care for management of the disease is enzyme replacement therapy (ERT). Sanofi's Fabrazyme and Shire's Replagal are the only approved ERTs in the EU; however in the U.S., only Fabrazyme has been approved.
Focus of current clinical trials is to improve the safety and efficacy profile of ERTs and introduction of novel oral therapies that can eliminate the need for intravenous infusions. Recently, Amicus Therapeutics' Galafold has been approved as the first oral chaperone therapy for the treatment of adults in the U.S., Canada, EU, Japan, Australia, Israel, and South Korea.
North America held the largest share in the Fabry disease treatment market in 2017, followed by Europe. The growth of the region can be attributed to higher adoption of novel therapies, favorable reimbursement policies, and better healthcare facilities. However, high cost of therapy with ERTs such as Fabrazyme is an impediment for the market in developing regions.
Fabry Disease Treatment Market Report Highlights:
- Intravenous route dominated the market with a market share of 65.9 % in 2023 and is also expected to grow at the fastest CAGR over the forecast period from 2024 to 2030.
- The enzyme replacement treatment segment dominated the market and accounted for a share of 72.3 % in 2023.
- North America commanded the leading market share of more than 45.1% in the Fabry disease treatment market, followed by Europe, in 2023
- APAC is likely to witness the fastest growth during the forecast period, followed by Latin America, due to increasing healthcare expenditure and rising patient population
Product Code: GVR-2-68038-747-6
Table of Contents
Chapter 1. Methodology and Scope
- 1.1. Market Segmentation and Scope
- 1.2. Market Definitions
- 1.3. Research Methodology
- 1.3.1. Information Procurement
- 1.3.2. Information or Data Analysis
- 1.3.3. Market Formulation & Data Visualization
- 1.3.4. Data Validation & Publishing
- 1.4. Research Scope and Assumptions
- 1.4.1. List of Data Sources
Chapter 2. Executive Summary
- 2.1. Market Outlook
- 2.2. Segment Outlook
- 2.3. Competitive Insights
Chapter 3. Fabry Disease Market Variables, Trends, & Scope
- 3.1. Market Introduction/Lineage Outlook
- 3.2. Market Size and Growth Prospects (USD Million)
- 3.3. Market Dynamics
- 3.3.1. Market Drivers Analysis
- 3.3.2. Market Restraints Analysis
- 3.4. Fabry Disease Market Analysis Tools
- 3.4.1. Porter's Analysis
- 3.4.1.1. Bargaining power of the suppliers
- 3.4.1.2. Bargaining power of the buyers
- 3.4.1.3. Threats of substitution
- 3.4.1.4. Threats from new entrants
- 3.4.1.5. Competitive rivalry
- 3.4.2. PESTEL Analysis
- 3.4.2.1. Political landscape
- 3.4.2.2. Economic and Social landscape
- 3.4.2.3. Technological landscape
- 3.4.2.4. Environmental landscape
- 3.4.2.5. Legal landscape
- 3.4.1. Porter's Analysis
Chapter 4. Fabry Disease Market: Treatment Estimates & Trend Analysis
- 4.1. Segment Dashboard
- 4.2. Fabry Disease Market: Treatment Movement Analysis, USD Million, 2023 & 2030
- 4.3. Enzyme Replacement Therapy
- 4.3.1. Enzyme Replacement Therapy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
- 4.4. Chaperone Treatment
- 4.4.1. Chaperone Treatment Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
- 4.5. Substrate Reduction Therapy
- 4.5.1. Substrate Reduction Therapy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
- 4.6. Other Diseases
- 4.6.1. Other Diseases Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
Chapter 5. Fabry Disease Market: Route of Administration Estimates & Trend Analysis
- 5.1. Segment Dashboard
- 5.2. Fabry Disease Market: Route of Administration Movement Analysis, USD Million, 2023 & 2030
- 5.3. Intravenous Route
- 5.3.1. Intravenous Route Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
- 5.4. Oral Route
- 5.4.1. Oral Route Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
Chapter 6. Fabry Disease Market: Distribution Channel Outlook Estimates & Trend Analysis
- 6.1. Segment Dashboard
- 6.2. Fabry Disease Market: Distribution Channel Movement Analysis, USD Million, 2023 & 2030
- 6.3. Hospital Pharmacy
- 6.3.1. Hospital Pharmacy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
- 6.4. Retail Pharmacy
- 6.4.1. Retail Pharmacy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
- 6.5. Online Pharmacy
- 6.5.1. Online Pharmacy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
Chapter 7. Fabry Disease Market: Regional Estimates & Trend Analysis
- 7.1. Fabry Disease Market Share, By Region, 2023 & 2030, USD Million
- 7.2. North America
- 7.2.1. North America Fabry Disease Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.2.2. U.S.
- 7.2.2.1. U.S. Fabry Disease Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.2.3. Canada
- 7.2.3.1. Canada Fabry Disease Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.2.4. Mexico
- 7.2.4.1. Mexico Fabry Disease Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.3. Europe
- 7.3.1. Europe Fabry Disease Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.3.2. UK
- 7.3.2.1. UK Fabry Disease Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.3.3. Germany
- 7.3.3.1. Germany Fabry Disease Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.3.4. France
- 7.3.4.1. France Fabry Disease Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.3.5. Italy
- 7.3.5.1. Italy Fabry Disease Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.3.6. Spain
- 7.3.6.1. Spain Fabry Disease Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.3.7. Denmark
- 7.3.7.1. Denmark Fabry Disease Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.3.8. Sweden
- 7.3.8.1. Sweden Fabry Disease Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.3.9. Norway
- 7.3.9.1. Norway Fabry Disease Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.4. Asia Pacific
- 7.4.1. Asia Pacific Fabry Disease Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.4.2. Japan
- 7.4.2.1. Japan Fabry Disease Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.4.3. China
- 7.4.3.1. China Fabry Disease Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.4.4. India
- 7.4.4.1. India Fabry Disease Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.4.5. South Korea
- 7.4.5.1. South Korea Fabry Disease Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.4.6. Australia
- 7.4.6.1. Australia Fabry Disease Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.4.7. South Korea
- 7.4.7.1. South Korea Fabry Disease Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.4.8. Thailand
- 7.4.8.1. Thailand Fabry Disease Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.5. Latin America
- 7.5.1. Latin America Fabry Disease Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.5.2. Brazil
- 7.5.2.1. Brazil Fabry Disease Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.5.3. Argentina
- 7.5.3.1. Argentina Fabry Disease Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.6. Middle East and Africa
- 7.6.1. Middle East and Africa Fabry Disease Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.6.2. South Africa
- 7.6.2.1. South Africa Fabry Disease Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.6.3. Saudi Arabia
- 7.6.3.1. Saudi Arabia Fabry Disease Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.6.4. UAE
- 7.6.4.1. UAE Fabry Disease Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.6.5. Kuwait
- 7.6.5.1. Kuwait Fabry Disease Market Estimates and Forecasts, 2018 - 2030 (USD Million)
Chapter 8. Competitive Landscape
- 8.1. Recent Developments & Impact Analysis by Key Market Participants
- 8.2. Company Categorization
- 8.3. Company Heat Map Analysis
- 8.4. Company Profiles
- 8.4.1. Sanofi S.A.
- 8.4.1.1. Participant's Overview
- 8.4.1.2. Financial Performance
- 8.4.1.3. Product Benchmarking
- 8.4.1.4. Recent Developments/ Strategic Initiatives
- 8.4.2. Shire Plc.
- 8.4.2.1. Participant's Overview
- 8.4.2.2. Financial Performance
- 8.4.2.3. Product Benchmarking
- 8.4.2.4. Recent Developments/ Strategic Initiatives
- 8.4.3. Amicus Therapeutics Inc.
- 8.4.3.1. Participant's Overview
- 8.4.3.2. Financial Performance
- 8.4.3.3. Product Benchmarking
- 8.4.3.4. Recent Developments/ Strategic Initiatives
- 8.4.4. ISU Abxis Co Ltd.
- 8.4.4.1. Participant's Overview
- 8.4.4.2. Financial Performance
- 8.4.4.3. Product Benchmarking
- 8.4.4.4. Recent Developments/ Strategic Initiatives
- 8.4.5. JCR Pharmaceuticals Co Ltd.
- 8.4.5.1. Participant's Overview
- 8.4.5.2. Financial Performance
- 8.4.5.3. Product Benchmarking
- 8.4.5.4. Recent Developments/ Strategic Initiatives
- 8.4.6. Protalix Biotherapeutics Inc.
- 8.4.6.1. Participant's Overview
- 8.4.6.2. Financial Performance
- 8.4.6.3. Product Benchmarking
- 8.4.6.4. Recent Developments/ Strategic Initiatives
- 8.4.7. Idorsia Pharmaceuticals Ltd.
- 8.4.7.1. Participant's Overview
- 8.4.7.2. Financial Performance
- 8.4.7.3. Product Benchmarking
- 8.4.7.4. Recent Developments/ Strategic Initiatives
- 8.4.8. Avrobio Inc.
- 8.4.8.1. Participant's Overview
- 8.4.8.2. Financial Performance
- 8.4.8.3. Product Benchmarking
- 8.4.8.4. Recent Developments/ Strategic Initiatives
- 8.4.1. Sanofi S.A.
Have a question?
SELECT AN OPTION
Have a question?
Questions? Please give us a call or visit the contact form.